Published in Proc Natl Acad Sci U S A on May 28, 2009
The molecular biology of head and neck cancer. Nat Rev Cancer (2010) 9.84
Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol (2010) 4.94
Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol (2012) 2.46
Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell (2011) 2.46
Inside the human cancer tyrosine phosphatome. Nat Rev Cancer (2011) 2.38
Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling? Cell Div (2010) 1.70
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev (2013) 1.55
STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One (2012) 1.33
A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer (2010) 1.33
Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proc Natl Acad Sci U S A (2010) 1.30
Recent advances in the molecular understanding of glioblastoma. J Neurooncol (2012) 1.29
Identification and functional analysis of 9p24 amplified genes in human breast cancer. Oncogene (2011) 1.19
Evaluation of microsatellite variation in the 1000 Genomes Project pilot studies is indicative of the quality and utility of the raw data and alignments. Genomics (2011) 1.18
Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene (2010) 1.17
Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget (2014) 1.11
Gene deletions and amplifications in human hepatocellular carcinomas: correlation with hepatocyte growth regulation. Am J Pathol (2012) 1.10
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A (2014) 1.01
Receptor protein tyrosine phosphatases and cancer: new insights from structural biology. Cell Adh Migr (2012) 1.00
Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res (2012) 0.99
Critical analysis of the potential for targeting STAT3 in human malignancy. Onco Targets Ther (2013) 0.99
Cross-talk between phospho-STAT3 and PLCγ1 plays a critical role in colorectal tumorigenesis. Mol Cancer Res (2011) 0.98
Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis. Oncoscience (2014) 0.98
Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. Proc Natl Acad Sci U S A (2014) 0.93
Protein tyrosine phosphatases in glioma biology. Acta Neuropathol (2009) 0.92
Genomic profiling of advanced-stage oral cancers reveals chromosome 11q alterations as markers of poor clinical outcome. PLoS One (2011) 0.92
Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene. Mol Cancer (2012) 0.91
NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age. Expert Rev Neurother (2014) 0.91
Toxicogenomic analysis of exposure to TCDD, PCB126 and PCB153: identification of genomic biomarkers of exposure to AhR ligands. BMC Genomics (2010) 0.89
Focal DNA copy number changes in neuroblastoma target MYCN regulated genes. PLoS One (2013) 0.88
Epigenetic regulation of wnt pathway antagonists in human glioblastoma multiforme. Genes Cancer (2010) 0.87
Studying a complex tumor: potential and pitfalls. Cancer J (2012) 0.87
Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. Oncotarget (2013) 0.87
Genetic alterations of protein tyrosine phosphatases in human cancers. Oncogene (2014) 0.86
Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44. Exp Ther Med (2011) 0.86
Determinants of the extent and duration of STAT3 signaling. JAKSTAT (2012) 0.85
Genomics of squamous cell lung cancer. Oncologist (2013) 0.85
Novel human genetic variants associated with extrapulmonary tuberculosis: a pilot genome wide association study. BMC Res Notes (2011) 0.85
Tailoring tyrosine kinase inhibitors to fit the lung cancer genome. Transl Oncol (2011) 0.83
Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors. PLoS One (2014) 0.82
The prognostic role of intragenic copy number breakpoints and identification of novel fusion genes in paediatric high grade glioma. Acta Neuropathol Commun (2014) 0.82
Increased metastasis with loss of E2F2 in Myc-driven tumors. Oncotarget (2015) 0.82
PTPRD silencing by DNA hypermethylation decreases insulin receptor signaling and leads to type 2 diabetes. Oncotarget (2015) 0.82
Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis. Oncotarget (2014) 0.81
Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity. Cancer Biol Ther (2014) 0.81
Tumor-derived extracellular fragments of receptor protein tyrosine phosphatases (RPTPs) as cancer molecular diagnostic tools. Anticancer Agents Med Chem (2011) 0.81
Reduced expression of PTPRD correlates with poor prognosis in gastric adenocarcinoma. PLoS One (2014) 0.81
Protein tyrosine phosphatases as wardens of STAT signaling. JAKSTAT (2014) 0.80
Cancer driver-passenger distinction via sporadic human and dog cancer comparison: a proof-of-principle study with colorectal cancer. Oncogene (2013) 0.80
Candidate genes involving in tumorigenesis of cholangiocarcinoma induced by Opisthorchis viverrini infection. Parasitol Res (2011) 0.80
Inositol Polyphosphate-5-Phosphatase F (INPP5F) inhibits STAT3 activity and suppresses gliomas tumorigenicity. Sci Rep (2014) 0.79
The genetics of nodal marginal zone lymphoma. Blood (2016) 0.79
Classical pathology and mutational load of breast cancer - integration of two worlds. J Pathol Clin Res (2015) 0.78
Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma. Hum Mutat (2014) 0.78
Genome-Wide Loss of Heterozygosity and DNA Copy Number Aberration in HPV-Negative Oral Squamous Cell Carcinoma and Their Associations with Disease-Specific Survival. PLoS One (2015) 0.77
Receptor-type protein tyrosine phosphatases in cancer. Chin J Cancer (2014) 0.77
Host genetic variants and gene expression patterns associated with Epstein-Barr virus copy number in lymphoblastoid cell lines. PLoS One (2014) 0.77
Missing-in-Metastasis regulates cell motility and invasion via PTPδ-mediated changes in SRC activity. Biochem J (2015) 0.77
Losing balance: Hardy-Weinberg disequilibrium as a marker for recurrent loss-of-heterozygosity in cancer. Hum Mol Genet (2011) 0.77
Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer. PLoS One (2015) 0.77
Transgelin increases metastatic potential of colorectal cancer cells in vivo and alters expression of genes involved in cell motility. BMC Cancer (2016) 0.77
Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer. Oncol Rep (2015) 0.76
PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2. Oncogene (2016) 0.76
Allelotypes of lung adenocarcinomas featuring ALK fusion demonstrate fewer onco- and suppressor gene changes. BMC Cancer (2013) 0.76
STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia (2013) 0.76
Genomic Alteration in Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines Inferred from Karyotyping, Molecular Cytogenetics, and Array Comparative Genomic Hybridization. PLoS One (2016) 0.76
PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. J Hypertens (2015) 0.76
Tobacco habituated and non-habituated subjects exhibit different mutational spectrums in head and neck squamous cell carcinoma. 3 Biotech (2014) 0.75
Abundant copy-number loss of CYCLOPS and STOP genes in gastric adenocarcinoma. Gastric Cancer (2015) 0.75
Genetic variants in PTPRD and risk of gestational diabetes mellitus. Oncotarget (2016) 0.75
Frequent HRAS Mutations in Malignant Ectomesenchymoma: Overlapping Genetic Abnormalities With Embryonal Rhabdomyosarcoma. Am J Surg Pathol (2016) 0.75
Characterization of differential protein tethering at the plasma membrane in response to epidermal growth factor signaling. J Proteome Res (2012) 0.75
Role of STAT3 in Genesis and Progression of Human Malignant Gliomas. Mol Neurobiol (2016) 0.75
Specific genomic aberrations predict survival, but low mutation rate in cancer hot spots, in clear cell renal cell carcinoma. Appl Immunohistochem Mol Morphol (2015) 0.75
Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations. Cancer Cell (2016) 0.75
Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the JAK2 gene in non-small cell lung cancer. Oncotarget (2017) 0.75
Increased PTPRA expression leads to poor prognosis through c-Src activation and G1 phase progression in squamous cell lung cancer. Int J Oncol (2017) 0.75
A Joint Bayesian Model for Integrating Microarray and RNA Sequencing Transcriptomic Data. J Comput Biol (2017) 0.75
miR-500a-3p promotes cancer stem cells properties via STAT3 pathway in human hepatocellular carcinoma. J Exp Clin Cancer Res (2017) 0.75
miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut (2017) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Stat3 as an oncogene. Cell (1999) 17.39
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Oncogenic kinase signalling. Nature (2001) 16.30
Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science (1994) 11.33
Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A (2004) 9.42
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Principles of tumor suppression. Cell (2004) 5.52
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71
Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (2004) 4.67
Protein-tyrosine phosphatases and cancer. Nat Rev Cancer (2006) 3.65
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell (2007) 3.58
Cancer genetics. Nature (2001) 2.84
Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res (2001) 2.78
Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene (2002) 2.69
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res (2008) 2.55
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell (2005) 2.51
Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci U S A (2007) 1.87
Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer (2003) 1.85
Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med (2008) 1.70
High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res (2006) 1.68
Identification of chromosome arm 9p as the most frequent target of homozygous deletions in lung cancer. Genes Chromosomes Cancer (2005) 1.60
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res (2003) 1.48
Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis. Genes Chromosomes Cancer (2007) 1.39
Structural requirements for signal transducer and activator of transcription 3 binding to phosphotyrosine ligands containing the YXXQ motif. J Biol Chem (2004) 1.28
Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter. Oncogene (2007) 1.23
JSI-124 inhibits glioblastoma multiforme cell proliferation through G(2)/M cell cycle arrest and apoptosis augment. Cancer Biol Ther (2008) 1.12
LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br J Cancer (2009) 1.10
Single nucleotide polymorphism array analysis defines a specific genetic fingerprint for well-differentiated cutaneous SCCs. J Invest Dermatol (2009) 1.08
Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Res (2001) 1.03
STAT3 silencing with lentivirus inhibits growth and induces apoptosis and differentiation of U251 cells. J Neurooncol (2008) 0.97
Molecular and cytogenetic analysis of chromosome 9 deletions in 75 malignant gliomas. Genes Chromosomes Cancer (1994) 0.97
CDKN2A is not the principal target of deletions on the short arm of chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin. Int J Cancer (2001) 0.86
The amino acid residues immediately carboxyl-terminal to the tyrosine phosphorylation site contribute to interleukin 6-specific activation of signal transducer and activator of transcription 3. J Biol Chem (1997) 0.85
Analysis of tumor suppressor gene on human chromosome 9 in mouse x human somatic cell hybrids. Somat Cell Mol Genet (1994) 0.78
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Human MicroRNA targets. PLoS Biol (2004) 34.51
A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 34.03
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell (2008) 28.29
Integration of biological networks and gene expression data using Cytoscape. Nat Protoc (2007) 27.10
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
MicroRNA targets in Drosophila. Genome Biol (2003) 23.59
Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature (2005) 23.04
Global mapping of the yeast genetic interaction network. Science (2004) 21.34
International network of cancer genome projects. Nature (2010) 20.35
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
The microRNA.org resource: targets and expression. Nucleic Acids Res (2007) 16.26
The HUPO PSI's molecular interaction format--a community standard for the representation of protein interaction data. Nat Biotechnol (2004) 16.08
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
Characterizing gene sets with FuncAssociate. Bioinformatics (2003) 14.10
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
Identification of microRNAs of the herpesvirus family. Nat Methods (2005) 12.98
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Identification of virus-encoded microRNAs. Science (2004) 12.56
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res (2011) 10.99
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
The BioPAX community standard for pathway data sharing. Nat Biotechnol (2010) 9.19
Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res (2010) 9.18
A novel class of small RNAs bind to MILI protein in mouse testes. Nature (2006) 8.80
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 8.67
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
The Systems Biology Graphical Notation. Nat Biotechnol (2009) 8.53
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
Gene expression profiling of gliomas strongly predicts survival. Cancer Res (2004) 7.79
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell (2008) 7.60
Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52
Mutual exclusivity analysis identifies oncogenic network modules. Genome Res (2011) 7.22
Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol (2010) 7.15
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol (2004) 6.95
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res (2006) 6.91
Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A (2007) 6.79
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A (2009) 6.78
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A (2005) 6.52
Emerging landscape of oncogenic signatures across human cancers. Nat Genet (2013) 6.48
miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol (2004) 6.44
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Glioblastoma stem-like cells give rise to tumour endothelium. Nature (2010) 6.18
Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest (2005) 6.10
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res (2013) 6.10